by | Sep 21, 2020 | Beverley, Stephen
— The creators used classical homologous recombination to remove both copies of the Leishmania major target of rapamycin (TOR3). This mutant was used to study TOR3’s suitability as a potential drug candidate.
Da Silva, L. M., & Beverley, S. M. (2010). Expansion of the target of rapamycin (T…
by | Sep 21, 2020 | Beverley, Stephen
— The creators used homologous gene recombination to delete the gene encoding inositol phosphoryl ceramide synthase (IPCS) from the genome of the protozoan parasite Leshmania major.
by | Sep 21, 2020 | Liu, Zhuoming, Whelan, Sean
— This is a large panel of variants in the SARS-CoV-2 spike protein incorporated into a VSV-vector. These were largely selected as escape mutants to neutralizing antibodies or were designed to probe the function of circulating viral variants. These constructs can be used to screen antibodies and solub…
by | Aug 24, 2020 | Holtzman, David
—
Anti-human hPLD3 antibody raised in mice. The antibody isotype is islgG2b.
by | Aug 21, 2020 | Sibley, Laurence
— Plasmids for expression of phenyl alanine tRNA synthase from Toxoplasma gondii, Plasmodium falciparum and Homo sapiens. These include wild type and various mutant forms.